Radiopharm Theranostics Limited (NASDAQ:RADX) is a biotechnology company with treatments for brain metastasis and prostate cancer. B. Riley lowered its share price target to $13 from $15 on November 26th. Clinical trials for RAD 101 and RAD 204 show promise, with potential for a Phase 3 trial targeting cerebral metastases.

Radiopharm Theranostics Limited (NASDAQ:RADX) reported positive updates on its treatment programs, including RAD 204’s phase 1 clinical trial for various cancers. RAD 101 is in a Phase 2b trial with FDA Fast Track Designation. The market potential for RAD 101 is significant, targeting 300,000 annual cerebral metastases cases in the US.

Investors see potential in RADX, but some believe other AI stocks offer higher returns and less risk. For those interested in an affordable AI stock that benefits from Trump tariffs and onshoring, check out a free report on the best short-term AI stock.

For more investment opportunities, check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” on Insider Monkey. No disclosures in this article.

Read more at Yahoo Finance: Radiopharm (RADX) Sees Slight Pessimism From Analysts